Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Michael O'Riordan

April 25, 2016

News Daily News

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Michael O'Riordan

April 25, 2016

News Daily News

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

Michael O'Riordan

April 25, 2016

News Daily News

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

L.A. McKeown

February 03, 2016

News Daily News

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

L.A. McKeown

February 03, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

Presentation TCTAP 2012

Indian TUXEDO Trial In Medically Treated Diabetics

Presenter: Upendra Kaul

April 26, 2012

Advertisement

糖尿病患者（即使需要胰岛素）中依维莫司支架优于紫杉醇支架：TUXEDO 分析

Everolimus Stent Better Than Paclitaxel Stent in Diabetic Patients, Even Those Requiring Insulin: TUXEDO Analysis

Análisis del TUXEDO: Los Stents de Everolimus son Mejores que los de Paclitaxel en Pacientes Diabéticos, Incluso en Insulinodependientes

糖尿病对 DES 治疗的患者的影响甚于病变复杂性

La Diabetes Influye Más que la Complejidad de la Enfermedad en Pacientes Tratados con SLF

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Indian TUXEDO Trial In Medically Treated Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content